80 related articles for article (PubMed ID: 27006491)
1. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.
Thielen N; Richter J; Baldauf M; Barbany G; Fioretos T; Giles F; Gjertsen BT; Hochhaus A; Schuurhuis GJ; Sopper S; Stenke L; Thunberg S; Wolf D; Ossenkoppele G; Porkka K; Janssen J; Mustjoki S
Clin Cancer Res; 2016 Aug; 22(16):4030-8. PubMed ID: 27006491
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
Hochhaus A; Mahon FX; le Coutre P; Petrov L; Janssen JJWM; Cross NCP; Rea D; Castagnetti F; Hellmann A; Rosti G; Gattermann N; Coronel MLP; Gutierrez MAE; Garcia-Gutierrez V; Vincenzi B; Dezzani L; Giles FJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1225-1233. PubMed ID: 28224300
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Hughes TP; Munhoz E; Aurelio Salvino M; Ong TC; Elhaddad A; Shortt J; Quach H; Pavlovsky C; Louw VJ; Shih LY; Turkina AG; Meillon L; Jin Y; Acharya S; Dalal D; Lipton JH
Br J Haematol; 2017 Oct; 179(2):219-228. PubMed ID: 28699641
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia.
Chaudhary N; Rahman K; Gupta P; Gupta R; Sarkar MK; Singh MK; Chandra D; Kumar S; Kashyap R
Int J Lab Hematol; 2024 May; ():. PubMed ID: 38711332
[TBL] [Abstract][Full Text] [Related]
5. Flow Cytometric Assessment of CD26-Positive Leukemic Stem Cells: A Rapid and Valuable Tool in the Diagnosis and Follow-Up of Chronic Myeloid Leukemia.
Kana S; John S; Basu D; Kar R; Nachiappa Ganesh R; Dubashi B
Cureus; 2024 Mar; 16(3):e56944. PubMed ID: 38665755
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and Apoptotic Effects of Luffa Cylindrica Leaves Extract against Acute Lymphoblastic Leukemic Stem Cells.
Yehia S; Abdel-Salam IM; Elgamal BM; El-Agamy B; Hamdy GM; Aldouski HM
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3661-3668. PubMed ID: 33369466
[TBL] [Abstract][Full Text] [Related]
7. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives.
Valent P; Sadovnik I; Peter B; Ivanov D; Schulenburg A; Hadzijusufovic E; Willmann M; Rülicke T; Herrmann H; Rabitsch W; Karlic H; Gleixner KV; Sperr WR; Hoermann G; Dahlhoff M; Pfeilstöcker M; Keil F; Lion T; Grunt TW
Expert Rev Hematol; 2023; 16(9):659-670. PubMed ID: 37493441
[TBL] [Abstract][Full Text] [Related]
8. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
9. Moving treatment-free remission into mainstream clinical practice in CML.
Hughes TP; Ross DM
Blood; 2016 Jul; 128(1):17-23. PubMed ID: 27013442
[TBL] [Abstract][Full Text] [Related]
10. Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.
Emole J; Talabi T; Pinilla-Ibarz J
Biologics; 2016; 10():23-31. PubMed ID: 27013862
[TBL] [Abstract][Full Text] [Related]
11. Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.
Jackson RC; Radivoyevitch T
AAPS J; 2016 Jul; 18(4):914-22. PubMed ID: 27007600
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
13. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.
Steegmann JL; Baccarani M; Breccia M; Casado LF; García-Gutiérrez V; Hochhaus A; Kim DW; Kim TD; Khoury HJ; Le Coutre P; Mayer J; Milojkovic D; Porkka K; Rea D; Rosti G; Saussele S; Hehlmann R; Clark RE
Leukemia; 2016 Aug; 30(8):1648-71. PubMed ID: 27121688
[TBL] [Abstract][Full Text] [Related]
14. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].
García-Gutiérrez V; Jiménez-Velasco A; Gómez-Casares MT; Sánchez-Guijo F; López-Sendón JL; Steegmann Olmedillas JL
Med Clin (Barc); 2016 Jun; 146(12):561.e1-8. PubMed ID: 27107729
[TBL] [Abstract][Full Text] [Related]
17. Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Soverini S; De Benedittis C; Mancini M; Martinelli G
Oncologist; 2016 May; 21(5):626-33. PubMed ID: 27032870
[TBL] [Abstract][Full Text] [Related]
18. Immunological off-target effects of imatinib.
Zitvogel L; Rusakiewicz S; Routy B; Ayyoub M; Kroemer G
Nat Rev Clin Oncol; 2016 Jul; 13(7):431-46. PubMed ID: 27030078
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
Culen M; Borsky M; Nemethova V; Razga F; Smejkal J; Jurcek T; Dvorakova D; Zackova D; Weinbergerova B; Semerad L; Sadovnik I; Eisenwort G; Herrmann H; Valent P; Mayer J; Racil Z
Oncotarget; 2016 May; 7(22):33016-24. PubMed ID: 27145281
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukaemia in Spain: Its presentation characteristics have changed. Spanish section of the EUTOS population-based registry.
Osorio S; Casado LF; Giraldo P; Maestro B; Andrade M; Redondo S; García-Gutiérrez V; Ayala R; Garcia N; Steegmann JL
Rev Clin Esp (Barc); 2016; 216(6):293-300. PubMed ID: 27061504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
